Intentional Mixture Of Two Or More Micro-organisms, Cells, Or Viruses Of Different Genera Patents (Class 424/93.3)
  • Patent number: 10357046
    Abstract: The present invention is directed to direct-fed microbials for use in improving the performance of an animal, improving the health of an animal, improving the environment of an animal, and combinations thereof. More particularly, the invention relates to isolated Bacillus strains 86 and 300, and strains having all of the identifying characteristics of these strains, for uses comprising the above-mentioned uses.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: July 23, 2019
    Assignee: Microbial Discovery Group, LLC
    Inventors: Michael R. King, Sona Son, Nathan Robert Augspurger, Joel Dean Spencer, Amy Lange, Michael D. Engelhardt
  • Patent number: 10349667
    Abstract: The present invention relates to feed compositions that can modify the feeding behavior of animals. Supplements can be added to no or low roughage rations that improve the performance of animals. In particular, the addition of calcium chloride to a low or no roughage ration can increase the number of feedings but decrease the amount of feeding per meal. This can result in promoting enhances feed conversion and better cost of feed to weight gain.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 16, 2019
    Assignee: Purina Animal Nutrition LLC
    Inventors: Ronald Ray Scott, James Christopher Forcherio
  • Patent number: 10188709
    Abstract: The present invention provides compositions for the treatment of phenylketonuria in mammals, as well as methods of preparing said compositions. The present invention also provides methods of treating phenylketonuria using the compositions of the invention.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: January 29, 2019
    Assignee: University of the Sciences
    Inventors: Anil P. D'Mello, Kush Patel
  • Patent number: 10172332
    Abstract: Provided is a method for regenerating hair follicles by transplanting a composition containing CD36-expressing dermal sheath cells (DSc) to a human. The composition may be prepared by sorting CD36-expressing dermal sheath cells from a hair follicle tissue by use of a cell-sorting technique along with an antibody to CD36. The composition may also contain dermal papilla cells (DPc).
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: January 8, 2019
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Yuzo Yoshida, Tsutomu Soma, Shigeyoshi Fujiwara
  • Patent number: 10172892
    Abstract: Described are strains including Enterococcus faecium strain 8G-1 (NRRL B-50173), Enterococcus faecium strain 8G-73 (NRRL B-50172), Bacillus pumilus strain 8G-134 (NRRL B-50174) and strains having all of the identifying characteristics of each of these strains. One or more of the strains can be used to reduce negative energy balance in a ruminant. They can also be used to improve other measures of ruminant health and/or performance. Methods of using the strains, alone and in combination, are described. Methods of making the strains are also provided.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 8, 2019
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Elizabeth Galbraith, Keith Mertz, Ajay Awati
  • Patent number: 10149867
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: December 11, 2018
    Assignees: The General Hospital Corporation, Ethicon Endo-Surgery, Inc., President and Fellows of Harvard College
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10124026
    Abstract: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourists.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: November 13, 2018
    Assignee: BIO-K PLUS INTERNATIONAL, INC.
    Inventor: Francois-Marie Luquet
  • Patent number: 10088484
    Abstract: A method of altering intercellular interactions between a combination of microorganisms includes contacting a combination of different species of microorganisms with at least one mucin. Isolated compositions include a combination of microorganisms and at least one mucin. One microorganism of the combination inhibits cell growth or promotes cell death of at least one other microorganism of a different species in the combination. The combination of microorganisms with the mucin results an increase in cell growth or a reduction in cell death, respectively, of the at least one other microorganism.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Katharina Ribbeck, Nicole Lynn Kavanaugh, Julia Yin-Ting Co, Erica Shapiro
  • Patent number: 10081562
    Abstract: The present invention provides compositions and methods for denitrification.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 25, 2018
    Assignee: BiOWiSH Technologies, Inc.
    Inventors: Michael S. Showell, John Gorsuch, Joseph Roberts
  • Patent number: 10058577
    Abstract: The present disclosure relates to thermo-stable/heat stable strain(s) of micro-organisms, obtaining such thermo-stable strains and incorporating them into food products. These strains are able to survive high temperatures for longer periods of time and thus food products containing such strains are therapeutically effective and beneficial for general health.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: August 28, 2018
    Assignee: TRIPHASE PHARMACEUTICALS PVT. LTD.
    Inventors: Desiraju Aditya, Desiraju Shrilakshmi, Sharieff Irfanulla, Prakash Abhilash
  • Patent number: 10022406
    Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: July 17, 2018
    Assignee: Crestovo Holdings LLC
    Inventor: Thomas Julius Borody
  • Patent number: 10004772
    Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: June 26, 2018
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 9993506
    Abstract: Methods for treating degenerative disc disease by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into at least one intervertebral disc or intervertebral space in need of treatment.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignee: BioDlogics, Inc.
    Inventor: Timothy R. Brahm
  • Patent number: 9986750
    Abstract: The present invention relates to pre-, pro-, and postbiotic compositions and methods of use for improving the health and nutrition of commercial livestock and companion pets.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: June 5, 2018
    Assignee: BiOWiSH Technologies Inc.
    Inventors: Richard S. Carpenter, JoElla Barnes, Michael Stanford Showell
  • Patent number: 9981011
    Abstract: A method of treating a wound in a diabetic patient is provided. The method includes administering a therapeutically effective amount of Chemokine (C-C motif) ligand 2 (CCL2) to a wound site. In another aspect, a method of treating a wound in a diabetic patient is provided. The method includes assaying a level of CCL2 in the diabetic patient relative to a level of CCL2 in a normal subject and administering a therapeutically effective amount of CCL2 to the diabetic patient.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Rush University Medical Center
    Inventor: Sasha Shafikhani
  • Patent number: 9974812
    Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: May 22, 2018
    Assignee: MESOBLAST, INC
    Inventors: Peter Ghosh, Silviu Itescu
  • Patent number: 9963718
    Abstract: The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 8, 2018
    Assignee: VIRATHERAPEUTICS GMBH
    Inventors: Dorothee Von Laer, Tsanan Heimann
  • Patent number: 9925222
    Abstract: Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 27, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Sridhar Mani, Subhajit Mukherjee
  • Patent number: 9907840
    Abstract: The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. A combination of either composition A (ASSURE PLUS®) and composition B (ASSURE®) or a combination of composition A (ASSURE PLUS®) and composition C (ASSURE GUARD®) may be administered to the equine.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: March 6, 2018
    Assignee: ALTERA INTERNATIONAL, LTD.
    Inventor: Jay A. Altman
  • Patent number: 9809503
    Abstract: A composition based on three strains of microorganisms to promote plant growth and serve as a plant protection product to protect plants from damaging influences including plant disease, pests or insects. The composition is comprised of isolated strains of Paenibacillus polymyxa M10, Azospirillum canadense B2, and Bacillus pumilus L13. A mineral mix is used to maintain the microorganism viable for a long time, maintaining high efficacy as a biopesticide and biofertilizer. The mineral mix combined with the fermented microorganisms is then further combined with a nutritional additive to enhance the biofertilizing and biopesticidal features of the composition. The resulting composition can be applied to plants in liquid form or to the soil in solid form.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: November 7, 2017
    Assignee: BIO AG CORP.
    Inventor: Lourdes Lanz
  • Patent number: 9783518
    Abstract: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: October 10, 2017
    Assignee: Toray Industries, Inc.
    Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
  • Patent number: 9724282
    Abstract: A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity. The stomatological composition includes at least one selected from the group consisting of lipase, protease and the antibody obtained from the hen egg yolk, citric acid and a metal salt of citric acid. A total amount of the lipase, the protease and the antibody obtained from the hen egg yolk is in the range of 0.001 to 10 wt %. When an amount of the citric acid is defined as “A” [wt %] and an amount of the metal salt of citric acid is defined as “B” [wt %], the following relation is satisfied: 0.005?A/B?1. Further, the stomatological composition of the present invention includes a polyglyceryl fatty acid ester or an amino acid-based ampholytic surfactant as a surfactant.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 8, 2017
    Assignee: Nippon Zettoc Co., Ltd.
    Inventors: Yasuyuki Tomabechi, Manami Sato, Misao Yasumuro
  • Patent number: 9706778
    Abstract: The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 18, 2017
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 9687000
    Abstract: Microbial strains, compositions, and methods of use thereof to enhance the growth and/or yield of a plant are provided. Also provided are materials and methods for presenting, inhibiting, or treating the development of plant pathogens or phytopathogenic diseases. The disclosure also provides non-naturally occurring plant and derivatives thereof such as plants artificially infected with a microbial strain of the invention.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: June 27, 2017
    Assignee: Monsanto Technology LLC
    Inventors: David T. Bullis, Christopher J. Grandlic, Ryan T. McCann, Janne S. Kerovuo
  • Patent number: 9669050
    Abstract: Disclosed is a composition for prophylaxis or treatment of hyperlipidemia, fatty liver, cardiovascular disease, or obesity including a compound represented by General Formula I as an effective ingredient: General Formula I S-(MS)p-(MS)q wherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: June 6, 2017
    Assignee: BENEBIOSIS CO., LTD.
    Inventor: Seung Woo Kang
  • Patent number: 9642372
    Abstract: Disclosed is an invention that relates to the formation of microsclerotial propagules by mycoparasitic fungi and the use of those microsclerotia for plant disease control. Representative microsclerotia propagules formed are from fungal species Trichoderma harzianum, Trichoderma lignorum, Trichoderma viridae, Trichoderma reesei, Trichoderma koningii, Trichoderma pseudokoningii, Trichoderma polysporum, Trichoderma hamatum, and Trichoderma asperellum.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: May 9, 2017
    Assignees: The United States of America, as represented by The Secretary of Agriculture, Empresa Brasileira de Pesquisa Agropecuaria
    Inventors: Mark A. Jackson, Gabriel M. Mascarin, Nilce Naomi Kobori
  • Patent number: 9644210
    Abstract: A method for a prophylaxis, suppression or elimination of an allergic reaction in a human, or for shifting the TH1-TH2 balance in a human body toward an increase of TH1 or a decrease of TH2 or both an increase in TH1 and a decrease in TH2, includes the steps of preparing a pharmaceutical composition having genomic DNA of at least one probiotic, gram-positive bacteria strain selected from the group Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium bifidum MG 20/5, Bifidumbacterium longum SP 07/3, Lactobacillus rhamnosus GG (92164) or a combination thereof, as an active ingredient, the at least one probiotic, gram-positive bacteria strain being present in the form of at least one of viable bacteria and inactivated bacteria, and administering to a human as suppository, vaginally, as a cream applied to skin, rectally, as a subcutaneous injection, as intravenous injection, as an inhalation liquid, or orally in combination with food.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: May 9, 2017
    Inventor: Jürgen Schrezenmeir
  • Patent number: 9642883
    Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: May 9, 2017
    Assignee: Chr. Hansen A/S
    Inventor: Tracey Jane Smith
  • Patent number: 9629881
    Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 25, 2017
    Assignee: REBIOTIX, INC.
    Inventor: Edwin J. Hlavka
  • Patent number: 9498503
    Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: November 22, 2016
    Assignee: Probiotical S.p.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna, Lorenzo Drago
  • Patent number: 9498502
    Abstract: Bifidobacterium breve CNCM I-3865 (NCC2950), a composition comprising Bifidobacterium breve CNCM I-3865 (NCC2950), and the use of Bifidobacterium breve CNCM I-3865 (NCC2950) in the prevention or treatment of allergic diarrhoea are provided. The Bifidobacterium breve CNCM I-3865 (NCC2950) can be in a non-replicating form and can be administered to at least partially treat allergic diarrhoea or at least partially reduce the risk of developing allergic diarrhoea.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 22, 2016
    Assignee: Nestec S.A.
    Inventors: Sophie Nutten, Annick Mercenier, Swantje Duncker
  • Patent number: 9463208
    Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: October 11, 2016
    Assignee: REBIOTIX, INC.
    Inventor: Edwin J. Hlavka
  • Patent number: 9433650
    Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: September 6, 2016
    Assignees: Academisch Medisch Centrum, Caelus Pharmaceuticals B.V.
    Inventors: Max Nieuwdorp, Willem Meindert De Vos
  • Patent number: 9414621
    Abstract: The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of offspring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection of offspring against infectious diseases.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: August 16, 2016
    Assignee: Nestec S.A.
    Inventors: Jalil Benyacoub, Stephanie Blum-Sperisen, Florence Rochat, Thierry Von der Weid
  • Patent number: 9370538
    Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: June 21, 2016
    Assignee: Nestec S.A.
    Inventors: Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
  • Patent number: 9320763
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: April 26, 2016
    Inventor: Thomas Julius Borody
  • Patent number: 9301984
    Abstract: Present invention features a method for controlling body weight, comprising Lactobacillus reuteri GMNL-263 with the deposition numbers of BCRC 910452 and CCTCC M 209263. Moreover, the invention also relates to a novel use of the composition or the isolated Lactobacillus strain for controlling body weight, whose mechanism is inhibiting biosynthesis of lipids and reducing formation of lipid droplets so as to control body weight.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 5, 2016
    Assignee: GenMont Biotech Inc.
    Inventors: Yi-Hsing Chen, Feng-Ching Hsieh, Po-Yung Chen
  • Patent number: 9217136
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: December 22, 2015
    Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan-Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
  • Patent number: 9168275
    Abstract: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 27, 2015
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventor: Sydney M. Finegold
  • Patent number: 9107429
    Abstract: A method of producing a water-in-oil product is described. The method comprises the step of: admixing a hydrophobic component with a water-in-oil emulsion to form said water-in-oil product, wherein said hydrophobic component comprises a probiotic in a hydrophobic medium.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: August 18, 2015
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventor: Paul Wassell
  • Patent number: 9101658
    Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: August 11, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Christopher H. Contag, Stephen Thorne
  • Patent number: 9050358
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: June 9, 2015
    Inventor: Thomas Julius Borody
  • Publication number: 20150147297
    Abstract: The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. A combination of either composition A (ASSURE PLUS®) and composition B (ASSURE®) or a combination of composition A (ASSURE PLUS®) and composition C (ASSURE GUARD®) may be administered to the equine.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventor: Jay A. Altman
  • Patent number: 9040036
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: May 26, 2015
    Inventor: Thomas Julius Borody
  • Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20150118190
    Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus, preferably strain ATCC53103, and Bifidobacterium animalis subsp. lactis, preferably strain DSM 15954, for use in reducing the duration and/or severity of upper respiratory tract infection (URI) in teenagers and adults. Further aspects of the invention relate to a composition comprising Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis for use in increasing the Health-Related Quality of Life (HRQL) in teenagers and adults having upper respiratory tract infection (URI), for reducing at least one and preferably several such as two, three, four or all of the symptoms of sore throat, scratchy throat, cough, hoarseness, chest congestion and for reducing the median severity score in teenagers and adults having upper respiratory tract infection (URI).
    Type: Application
    Filed: January 14, 2013
    Publication date: April 30, 2015
    Applicant: Chr. Hansen A/S
    Inventor: Tracey Jane Smith
  • Publication number: 20150118191
    Abstract: The present invention provides methods of designing panels of bacteriophages as therapeutic compositions against bacterial infections. The present invention also provides panels of bacteriophages for use in the prevention or treatment of bacterial infections.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: David Harper, Katy Blake
  • Patent number: 9011836
    Abstract: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: April 21, 2015
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Thomas G. Rehberger, Mari Ellen Davis, Ashley Baker
  • Patent number: 9011835
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: April 21, 2015
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Patent number: 9011837
    Abstract: Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: April 21, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Elazer R. Edelman, Brett Zani